Anti-atherosclerotic actions of azelaic acid, an end product of linoleic acid peroxidation, in mice

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 449-454

  Litvinov, Dmitry ^a   Selvarajan, Krithika ^a   Garelnabi, Mahdi ^a   Brophy, Larissa ^a   Parthasarathy, Sampath ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; CD68; Dicarboxylic acid; LDL receptor knockout mouse; Lipid peroxidation; Macrophages

Indexed keywords

ALDEHYDE DERIVATIVE; AZELAIC ACID; CARBOXYLIC ACID DERIVATIVE; CD68 ANTIGEN; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; FAT INTAKE; FEMALE; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; DICARBOXYLIC ACIDS; FEMALE; LINOLEIC ACID; LIPID PEROXIDATION; MICE; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 77950022007     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.076     Document Type: Article

References (31)

1. Berliner J.A., Watson A.D. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005, 353:9-11.
2. Parthasarathy S., Khan-Merchant N., Penumetcha M., Santanam N. Oxidative stress in cardiovascular disease. J Nucl Cardiol 2001, 8(3):379-389.
3. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320(14):915-924.
4. Parthasarathy S., Litvinov D., Selvarajan K., Garelnabi M. Lipid peroxidation and decomposition-conflicting roles in plaque vulnerability and stability. Biochim Biophys Acta 2008, 1781:221-231.
5. Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in atherogenesis. An appraisal. J Lipid Res 1999, 40:2143-2157.
6. Leonarduzzi G., Arkan M.C., Başaĝa H., Chiarpotto E., Sevanian A., Poli G. Lipid oxidation products in cell signaling. Free Radic Biol Med 2000, 28:1370-1378.
7. Hoff H.F., O'Neil J., Chisolm G.M., et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989, 9:538-549.
8. Steinbrecher U.P., Lougheed M., Kwan W.C., Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989, 264:15216-15223.
9. Leitinger N. Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 2003, 24:239-250.
10. Branch D.W., Mitchell M.D., Miller E., Palinski W., Witztum J.L. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 1994, 343:645-646.
11. Romero F.I., Khamashta M.A., Hughes G.R. Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus 2000, 9:206-209.
12. Sjögren P., Fredrikson G.N., Rosell M., et al. Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men. Metabolism 2008, 57:362-366.
13. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991, 11:81-128.
14. Dianzani M.U., Barrera G., Parola M. 4-Hydroxy-2,3-nonenal as a signal for cell function and differentiation. Acta Biochim Pol 1999, 46:61-75.
15. Raghavamenon A.C., Garelnabi M., Babu S., Aldrich A., Litvinov D., Parthasarathy S. α-Tocopherol is ineffective in preventing the decomposition of pre-formed lipid peroxides and may promote the accumulation of toxic aldehydes: a potential explanation for the failure of antioxidants to affect human atherosclerosis. Antioxid Redox Signal 2009, 11:1237-1248.
16. Conklin D., Prough R., Bhatanagar A. Aldehyde metabolism in the cardiovascular system. Mol Biosyst 2007, 3:136-150.
17. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics Int 2004, 11:36-42.
18. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
19. Santanam N., Parthasarathy S. Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases. J Clin Invest 1995, 95(6):2594-2600.
20. Akamatsu H., Komura J., Asada Y., Miyachi Y., Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991, 283:162-166.
21. Gooderham M. Rosacea and its topical management. Skin Therapy Lett 2009, 14:1-3.
22. Grego A.V., Mingrone G. Dicarboxylic acids, an alternate fuel substrate in parenteral nutrition: an update. Clin Nutr 1995, 14:143-148.
23. Mingrone G., Greco A.V., Nazzaro-Porro M., Passi S. Toxicity of azelaic acid. Drugs Exp Clin Res 1983, 9:447-455.
24. Passi S. Azelaic acid: biochemistry and metabolism. Acta Derm Veneorol Suppl-Stockh 1989, 143:8-13.
25. Schallreuter K.U., Wood J.M. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett 1987, 36:297-305.
26. Furman C., Rundlöf A.K., Larigauderie G., et al. Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins. Free Radic Biol Med 2004, 37:71-85.
27. Kawachi S., Takeda N., Sasaki A., et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:617-621.
28. Schuler-Luttmann S., Monnig G., Enbergs A., et al. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:E10-E15.
29. Kaplan R.C., McGinn A.P., Pollak M.N., et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 2007, 92:1319-1325.
30. Johnsen S.P., Hundborg H.H., Sørensen H.T., et al. Insulin-like growth factor (IGF)-I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005, 90:5937-5941.
31. Martin R.M., Gunnell D., Whitley E., et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 2008, 93:1331-1338.